BDX Add to watchlist
$155.52 0.21 (-0.13%)
After Hours: $155.52 +0.00 (+0.00%)
Last updated: Apr 15, 2026 23:09
52-Week Range
$155.52
$127.59 $155.52 $187.35

Fundamentals Overview

Becton, Dickinson and Company is in the middle of its 52-week range with premium valuation, trading relatively flat today.

Valuation premium

P/E 25.2 PEG 14.52 P/B 1.75 P/S 2.57

Intrinsic value (DCF)

+746.1% upside vs price

Profitability

Net margin 8%

Risk (Beta)

0.35 — lower vol

Earnings & growth

EPS $6.16 Rev -10.8% Profit -22.5% vs prior qtr

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 64% confidence Risk: Lower Volatility — Beta 0.35. Diversify and only invest what you can afford to lose.

Supporting (Buy):

DCF +746.1% upside vs price · Analyst grade: B+

Pressures (Sell):

Sentiment weakening (3 downgrades)

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$56.34B
P/E (TTM)
25.23
EPS (TTM)
$6.16
Dividend Yield
1.21%
52-Week Range
$127.59 - $187.35
Volume vs Avg
N/A
Beta
0.35

About

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and ...
Sector: Healthcare
Headquarters: US
Employees: 70,000
IPO Date: Feb 1973
Website: www.bd.com
Beta: 0.35 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: B+. Recent institutional grades: majority downgrades. Current institutional positions: Buy: 7, Equal Weight: 2, Market Perform: 1, Neutral: 8, Overweight: 8, Sector Perform: 4.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $1,315.87; current price is $155.52. That’s a +746.1% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 25.23
DCF value (model) $1,315.87 (746.1% upside)
PEG (TTM) 14.52
P/B (TTM) 1.75
P/S (TTM) 2.57
P/FCF (TTM) 21.42
Liquidity & enterprise
Current Ratio (TTM) 1.05
Quick Ratio (TTM) 0.58
Cash Ratio (TTM) 0.12
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 8.01%
Gross margin (TTM) 45.76%
Operating margin (TTM) 12.4%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for BDX.

Analyst Sentiment at a Glance

B+ Sentiment Weakening
Buy 7Equal Weight 2Market Perform 1Neutral 8Overweight 8Sector Perform 4
0 upgrades, 3 downgrades
Price Target Consensus
Current $155.52
Median $169.51
Consensus $174.69
Low consensus $165.09
High consensus $202.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Argus Research maintain Buy Buy 2026-03-23
Citigroup maintain Buy Buy 2026-02-11
Jefferies maintain Buy Buy 2026-02-10
JP Morgan maintain Neutral Neutral 2026-02-10
Piper Sandler maintain Neutral Neutral 2026-02-10
RBC Capital maintain Sector Perform Sector Perform 2026-02-10
Wells Fargo maintain Equal Weight Equal Weight 2026-02-10
Citigroup maintain Buy Buy 2026-02-10
Piper Sandler maintain Neutral Neutral 2026-01-28
Stifel maintain Buy Buy 2026-01-07
B of A Securities maintain Neutral Neutral 2026-01-05
RBC Capital maintain Sector Perform Sector Perform 2025-12-17
Morgan Stanley maintain Overweight Overweight 2025-12-02
Piper Sandler maintain Neutral Neutral 2025-11-07
RBC Capital maintain Sector Perform Sector Perform 2025-11-07
RBC Capital maintain Sector Perform Sector Perform 2025-10-16
Morgan Stanley maintain Overweight Overweight 2025-08-11
Wells Fargo maintain Equal Weight Equal Weight 2025-08-08
Piper Sandler maintain Neutral Neutral 2025-08-08
Barclays maintain Overweight Overweight 2025-06-03
Citigroup downgrade Buy Neutral 2025-05-22
Morgan Stanley maintain Overweight Overweight 2025-05-06
Stifel maintain Buy Buy 2025-05-02
Piper Sandler downgrade Overweight Neutral 2025-05-02
Citigroup maintain Buy Buy 2025-05-01
William Blair downgrade Outperform Market Perform 2025-05-01
Piper Sandler maintain Overweight Overweight 2025-04-23
Barclays maintain Overweight Overweight 2025-04-07
Barclays maintain Overweight Overweight 2025-02-14
Piper Sandler maintain Overweight Overweight 2025-01-28